Are DNA damage response kinases a target for the differentiation treatment of acute myeloid leukemia?
{{output}}
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy characterized by the expansion of hematopoietic stem/progenitor cells (HPCs) blocked at different stages of maturation/differentiation. The poor outcome of AMLs necessitates therapeutic imp... ...
